Synaptic Wnt/GSK3 β Signaling Hub in Autism

Neural Plasticity

Volumn 2016, Issue , 2016, Pages

  Caracci, Mario O ^a,b   Avila, Miguel E ^a,b   De Ferrari, Giancarlo V ^a,b  

^a UNIVERSIDAD ANDRÉS BELLO   (Chile)

^b FONDAP   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3BETA; WNT PROTEIN;

AUTISM; BRAIN DEVELOPMENT; HUMAN; LEARNING DISORDER; LONG TERM POTENTIATION; NERVE CELL INHIBITION; NERVE CELL PLASTICITY; NERVE CELL STIMULATION; NERVE ENDING; NONHUMAN; PROTEIN PHOSPHORYLATION; REVIEW; SYNAPTIC TRANSMISSION; SYNAPTOGENESIS; WNT SIGNALING PATHWAY; ANIMAL; BRAIN; METABOLISM; SYNAPSE;

ANIMALS; AUTISM SPECTRUM DISORDER; BRAIN; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMANS; SYNAPSES; WNT SIGNALING PATHWAY;

EID: 84962730481     PISSN: 20905904     EISSN: 16875443     Source Type: Journal    
DOI: 10.1155/2016/9603751     Document Type: Review

References (132)

1. C. J. Newschaffer, L. A. Croen, J. Daniels et al., "The epidemiology of autism spectrum disorders, " Annual Review of Public Health, vol. 28, pp. 235-258, 2007.
2. S. S. Jeste and D. H. Geschwind, "Disentangling the heterogeneity of autism spectrum disorder through genetic findings, " Nature Reviews Neurology, vol. 10, no. 2, pp. 74-81, 2014.
3. R. E. Rosenberg, J. K. Law, G. Yenokyan, J. McGready, W. E. Kaufmann, and P. A. Law, "Characteristics and concordance of autism spectrum disorders among 277 twin pairs, " Archives of Pediatrics & Adolescent Medicine, vol. 163, no. 10, pp. 907-914, 2009.
4. C. Betancur, "Etiological heterogeneity in autism spectrum disorders:more than 100 genetic and genomic disorders and still counting, " Brain Research, vol. 1380, pp. 42-77, 2011.
5. B. S. Abrahams and D. H. Geschwind, "Advances in autism genetics: on the threshold of a new neurobiology, " Nature Reviews Genetics, vol. 9, no. 5, pp. 341-355, 2008.
6. N. Krumm, B. J. O'Roak, J. Shendure, and E. E. Eichler, "A de novo convergence of autism genetics and molecular neuroscience, " Trends inNeurosciences, vol. 37, no. 2, pp. 95-105, 2014.
7. R. Anney, L. Klei, D. Pinto et al., "Individual common variants exert weak effects on the risk for autism spectrum disorders, " Human Molecular Genetics, vol. 21, no. 21, pp. 4781-4792, 2012.
8. D. Levy, M. Ronemus, B. Yamrom et al., "Rare de novo and transmitted copy-number variation in autistic spectrum disorders, " Neuron, vol. 70, no. 5, pp. 886-897, 2011.
9. S. J. Sanders, A. G. Ercan-Sencicek, V. Hus et al., "Multiple recurrent de novo CNVs, including duplications of the 7q11. 23 Williams syndrome region, are strongly associatedwith autism, " Neuron, vol. 70, no. 5, pp. 863-885, 2011.
10. I. Iossifov, B. J. O'Roak, S. J. Sanders et al., "The contribution of de novo codingmutations to autism spectrumdisorder, " Nature, vol. 515, no. 7526, pp. 216-221, 2014.
11. S. J. Sanders, M. T. Murtha, A. R. Gupta et al., "De novo mutations revealed by whole-exome sequencing are strongly associated with autism, " Nature, vol. 485, no. 7397, pp. 237-241, 2012.
12. F. Hormozdiari, O. Penn, E. Borenstein, and E. E. Eichler, "The discovery of integrated gene networks for autism and related disorders, " Genome Research, vol. 25, no. 1, pp. 142-154, 2015.
13. B. J. O'Roak, L. Vives, S. Girirajan et al., "Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations, " Nature, vol. 484, no. 7397, pp. 246-250, 2012.
14. B. J. O'Roak, L. Vives, W. Fu et al., "Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders, " Science, vol. 338, no. 6114, pp. 1619-1622, 2012.
15. S. De Rubeis, X. He, A. P. Goldberg et al., "Synaptic, transcriptional and chromatin genes disrupted in autism, " Nature, vol. 515, no. 7526, pp. 209-215, 2014.
16. G. V. De Ferrari and R. T. Moon, "The ups and downs of Wnt signaling in prevalent neurological disorders, " Oncogene, vol. 25, no. 57, pp. 7545-7553, 2006.
17. N. D. Okerlund and B. N. R. Cheyette, "Synaptic Wnt signaling-a contributor to major psychiatric disorders" Journal of Neurodevelopmental Disorders, vol. 3, no. 2, pp. 162-174, 2011.
18. H. O. Kalkman, "A review of the evidence for the canonicalWnt pathway in autism spectrum disorders, " Molecular Autism, vol. 3, no. 1, article 10, 2012.
19. R. T. Moon, A. D. Kohn, G. V. De Ferrari, and A. Kaykas, "WNT and-catenin signalling: diseases and therapies, " Nature Reviews Genetics, vol. 5, no. 9, pp. 691-701, 2004.
20. X. He, M. Semenov, K. Tamai, and X. Zeng, "LDL receptorrelated proteins 5 and 6 in Wnt/-catenin signaling: Arrows point the way, " Development, vol. 131, no. 8, pp. 1663-1677, 2004.
21. T. V. Lipina, O. Kaidanovich-Beilin, S. Patel et al., "Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3, " Synapse, vol. 65, no. 3, pp. 234-248, 2011.
22. M. J. Hart, R. De Los Santos, I. N. Albert, B. Rubinfeld, and P. Polakis, "Downregulation of-catenin by human Axin and its association with the APC tumor suppressor,-catenin and GSK3, " Current Biology, vol. 8, no. 10, pp. 573-581, 1998.
23. H. Clevers and R. Nusse, "Wnt/-catenin signaling and disease, " Cell, vol. 149, no. 6, pp. 1192-1205, 2012.
24. H. Aberle, A. Bauer, J. Stappert, A. Kispert, and R. Kemler, "-catenin is a target for the ubiquitin-proteasome pathway, " The EMBO Journal, vol. 16, no. 13, pp. 3797-3804, 1997.
25. B. C. Mak, K.-I. Takemaru, H. L. Kenerson, R. T. Moon, andR. S. Yeung, "The tuberin-hamartin complex negatively regulates-catenin signaling activity, " The Journal of Biological Chemistry, vol. 278, no. 8, pp. 5947-5951, 2003.
26. B. C. Mak, H. L. Kenerson, L. D. Aicher, E. A. Barnes, and R. S. Yeung, "Aberrant-catenin signaling in tuberous sclerosis, " The American Journal of Pathology, vol. 167, no. 1, pp. 107-116, 2005.
27. T. H. Wassink, J. Piven, V. J. Vieland et al., "Evidence supporting WNT2 as an autism susceptibility gene, " American Journal of Medical Genetics, vol. 105, no. 5, pp. 406-413, 2001.
28. E. M. J. Boon, R. Van der Neut, M. Van de Wetering, H. Clevers, and S. T. Pals, "Wnt signaling regulates expression of the receptor tyrosine kinase Met in colorectal cancer, " Cancer Research, vol. 62, no. 18, pp. 5126-5128, 2002.
29. J. B. Tuynman, L. Vermeulen, E. M. Boon et al., "Cyclooxygenase-2 inhibition inhibits c-Met kinase activity andWnt activity in colon cancer, " Cancer Research, vol. 68, no. 4, pp. 1213-1220, 2008.
30. D. B. Campbell, J. S. Sutcliffe, P. J. Ebert et al., "A genetic variant that disrupts MET transcription is associated with autism, " Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 45, pp. 16834-16839, 2006.
31. C. Redies, N. Hertel, and C. A. Hbner, "Cadherins and neuropsychiatric disorders, " Brain Research, vol. 1470, pp. 130-144, 2012.
32. B. J. O'Roak, P. Deriziotis, C. Lee et al., "Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations, " Nature Genetics, vol. 43, no. 6, pp. 585-589, 2011.
33. B. A. Thompson, V. Tremblay, G. Lin, and D. A. Bochar, "CHD8 is an ATP-dependent chromatin remodeling factor that regulates-catenin target genes, " Molecular and Cellular Biology, vol. 28, no. 12, pp. 3894-3904, 2008.
34. J. Y. Hong, J.-I. Park, M. Lee et al., "Down's-syndrome-related kinase Dyrk1A modulates the p120-catenin-Kaiso trajectory of theWnt signaling pathway, " Journal of Cell Science, vol. 125, no. 3, pp. 561-569, 2012.
35. E. Courchesne, K. Pierce, C. M. Schumann et al., "Mapping early brain development in autism, " Neuron, vol. 56, no. 2, pp. 399-413, 2007.
36. J. de Ligt, M. H. Willemsen, B. W. M. Van Bon et al., "Diagnostic exome sequencing in persons with severe intellectual disability, " The New England Journal of Medicine, vol. 367, no. 20, pp. 1921-1929, 2012.
37. J. L. R. Rubenstein, "Three hypotheses for developmental defects that may underlie some forms of autism spectrum disorder, " Current Opinion in Neurology, vol. 23, no. 2, pp. 118-123, 2010.
38. S. Vattikuti and C. C. Chow, "A computational model for cerebral cortical dysfunction in autism spectrum disorders, " Biological Psychiatry, vol. 67, no. 7, pp. 672-678, 2010.
39. O. Yizhar, L. E. Fenno, M. Prigge et al., "Neocortical excitation/inhibition balance in information processing and social dysfunction, " Nature, vol. 477, no. 7363, pp. 171-178, 2011.
40. H. Y. Zoghbi andM. F. Bear, "Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities, " Cold Spring Harbor Perspectives in Biology, vol. 4, no. 3, Article ID a009886, 2012.
41. R. Tuchman and I. Rapin, "Epilepsy in autism, " The Lancet Neurology, vol. 1, no. 6, pp. 352-358, 2002.
42. I. E. Scheffer and S. F. Berkovic, "The genetics of human epilepsy, " Trends in Pharmacological Sciences, vol. 24, no. 8, pp. 428-433, 2003.
43. K. Staley, "Molecular mechanisms of epilepsy, " Nature Neuroscience, vol. 18, no. 3, pp. 367-372, 2015.
44. G. V. De Ferrari and and N. C. Inestrosa, "Wnt signaling function in Alzheimer's disease, " Brain Research Reviews, vol. 33, no. 1, pp. 1-12, 2000.
45. A. Ahmad-Annuar, L. Ciani, I. Simeonidis et al., "Signaling across the synapse: a role for Wnt and Dishevelled in presynaptic assembly and neurotransmitter release, " Journal of Cell Biology, vol. 174, no. 1, pp. 127-139, 2006.
46. N. C. Inestrosa and E. Arenas, "Emerging roles of Wnts in the adult nervous system, " Nature Reviews Neuroscience, vol. 11, no. 2, pp. 77-86, 2010.
47. L. Ciani, K. A. Boyle, E. Dickins et al., "Wnt7a signaling promotes dendritic spine growth and synaptic strength through Ca2dependent protein kinase II, " Proceedings of the National Academy of Sciences, vol. 108, no. 26, pp. 10732-10737, 2011.
48. G. V. De Ferrari, M. E. Avila, M. A. Medina, E. Prez-Palma, B. I. Bustos, and M. A. Alarcn, "Wnt/-catenin signaling in Alzheimer's disease, " CNS and Neurological Disorders-Drug Targets, vol. 13, no. 5, pp. 745-754, 2014.
49. N. Itasaki, C. M. Jones, S. Mercurio et al., "Wise, a contextdependent activator and inhibitor of Wnt signalling, " Development, vol. 130, no. 18, pp. 4295-4305, 2003.
50. S. A. Ettenberg, O. Charlat, M. P. Daley et al., "Inhibition of tumorigenesis driven by differentWnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 35, pp. 15473-15478, 2010.
51. A. Caricasole, T. Ferraro, L. Iacovelli et al., "Functional characterization of WNT7A signaling in PC12 cells: interaction with a FZD5LRP6 receptor complex and modulation by Dickkopf proteins, "The Journal of Biological Chemistry, vol. 278, no. 39, pp. 37024-37031, 2003.
52. K. Sharma, S.-Y. Choi, Y. Zhang et al., "High-throughput genetic screen for synaptogenic factors: identification of LRP6 as critical for excitatory synapse development, " Cell Reports, vol. 5, no. 5, pp. 1330-1341, 2013.
53. J. Chen, S. P. Chang, and S.-J. Tang, "Activity-dependent synaptic Wnt release regulates hippocampal long term potentiation, " The Journal of Biological Chemistry, vol. 281, no. 17, pp. 11910-11916, 2006.
54. M. E. Avila, F. J. Seplveda, C. F. Burgos et al., "Canonical Wnt3amodulates intracellular calciumand enhances excitatory neurotransmission in hippocampal neurons, " The Journal of Biological Chemistry, vol. 285, no. 24, pp. 18939-18947, 2010.
55. W. Cerpa, J. A. Godoy, I. Alfaro et al., "Wnt-7a modulates the synaptic vesicle cycle and synaptic transmission in hippocampal neurons, " The Journal of Biological Chemistry, vol. 283, no. 9, pp. 5918-5927, 2008.
56. N. Lijam, R. Paylor, M. P. McDonald et al., "Social interaction and sensorimotor gating abnormalities in mice lacking Dvl1, " Cell, vol. 90, no. 5, pp. 895-905, 1997.
57. F. Cesca, P. Baldelli, F. Valtorta, andF. Benfenati, "The synapsins: key actors of synapse function and plasticity, " Progress in Neurobiology, vol. 91, no. 4, pp. 313-348, 2010.
58. A. Fassio, L. Patry, S. Congia et al., "SYN1 loss-of-function mutations in autism and partial epilepsy cause impaired synaptic function, " Human Molecular Genetics, vol. 20, no. 12, pp. 2297-2307, 2011.
59. A. Corradi, M. Fadda, A. Piton et al., "SYN2 is an autism predisposing gene: loss-offunction mutations alter synaptic vesicle cycling and axon outgrowth, " Human Molecular Genetics, vol. 23, no. 1, Article ID ddt401, pp. 90-103, 2014.
60. B. Greco, F. Managò, V. Tucci, H.-T. Kao, F. Valtorta, and F. Benfenati, "Autism-related behavioral abnormalities in synapsin knockout mice, " Behavioural Brain Research, vol. 251, pp. 65-74, 2013.
61. A. C. Hall, F. R. Lucas, and P. C. Salinas, "Axonal remodeling and synaptic differentiation in the cerebellum is regulated by WNT-7a signaling, " Cell, vol. 100, no. 5, pp. 525-535, 2000.
62. C. Hdar, R. Assar, M. Colombres et al., "Genome-wide identification of newWnt/-catenin target genes in the human genome using CART method, " BMC Genomics, vol. 11, no. 1, article 348, 2010.
63. J. L. Mohn, J. Alexander, A. Pirone et al., "Adenomatous polyposis coli protein deletion leads to cognitive and autismlike disabilities, " Molecular Psychiatry, vol. 19, no. 10, pp. 1133-1142, 2014.
64. S. Kishida, K. Hamao, M. Inoue et al., "Dvl regulates endo-and exocytotic processes through binding to synaptotagmin, " Genes to Cells, vol. 12, no. 1, pp. 49-61, 2007.
65. S. X. Bamji, K. Shimazu, N. Kimes et al., "Role of beta-catenin in synaptic vesicle localization and presynaptic assembly, " Neuron, vol. 40, no. 4, pp. 719-731, 2003.
66. Y. Iwai, Y. Hirota, K. Ozaki, H. Okano, M. Takeichi, and T. Uemura, "DN-cadherin is required for spatial arrangement of nerve terminals and ultrastructural organization of synapses, " Molecular and Cellular Neuroscience, vol. 19, no. 3, pp. 375-388, 2002.
67. K. Jngling, V. Eulenburg, R. Moore, R. Kemler, V. Lessmann, and K. Gottmann, "N-cadherin transsynaptically regulates short-term plasticity at glutamatergic synapses in embryonic stem cell-derived neurons, " The Journal of Neuroscience, vol. 26, no. 26, pp. 6968-6978, 2006.
68. Y. Sun, M. Aiga, E. Yoshida, P. O. Humbert, and S. X. Bamji, "Scribble interacts with-catenin to localize synaptic vesicles to synapses, " Molecular Biology of the Cell, vol. 20, no. 14, pp. 3390-3400, 2009.
69. H. Togashi, K. Abe, A. Mizoguchi, K. Takaoka, O. Chisaka, and M. Takeichi, "Cadherin regulates dendritic spine morphogenesis, " Neuron, vol. 35, no. 1, pp. 77-89, 2002.
70. S. X. Bamji, B. Rico, N. Kimes, and L. F. Reichardt, "BDNF mobilizes synaptic vesicles and enhances synapse formation by disrupting cadherin-catenin interactions, " The Journal of Cell Biology, vol. 174, no. 2, pp. 289-299, 2006.
71. J. J. Connolly, J. T. Glessner, and H. Hakonarson, "A genomewide association study of autism incorporating autism diagnostic interview-revised, autism diagnostic observation schedule, and social responsiveness scale, " Child Development, vol. 84, no. 1, pp. 17-33, 2013.
72. S.-H. Lee, I.-F. Peng, Y. G. Ng et al., "Synapses are regulated by the cytoplasmic tyrosine kinase Fer in a pathway mediated by p120catenin, Fer, SHP-2, and-catenin, " The Journal of Cell Biology, vol. 183, no. 5, pp. 893-908, 2008.
73. M. D. David, A. Yeramian, M. Duñach et al., "Signalling by neurotrophins and hepatocyte growth factor regulates axon morphogenesis by differential-catenin phosphorylation, " Journal of Cell Science, vol. 121, no. 16, pp. 2718-2730, 2008.
74. W. Cerpa, A. Gambrill, N. C. Inestrosa, and A. Barria, "Regulation of NMDA-receptor synaptic transmission byWnt signaling, " The Journal of Neuroscience, vol. 31, no. 26, pp. 9466-9471, 2011.
75. L. Varela-Nallar, I. E. Alfaro, F. G. Serrano, J. Parodi, and N. C. Inestrosa, "Wingless-type family member 5A (Wnt-5a) stimulates synaptic differentiation and function of glutamatergic synapses, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 49, pp. 21164-21169, 2010.
76. S. Cohen and M. E. Greenberg, "Communication between the synapse and the nucleus in neuronal development, plasticity, and disease, " Annual Review of Cell and Developmental Biology, vol. 24, pp. 183-209, 2008.
77. M. S. Arrzola, L. Varela-Nallar, M. Colombres et al., "Calcium/calmodulin-dependent protein kinase type IV is a target gene of the Wnt/-catenin signaling pathway, " Journal of Cellular Physiology, vol. 221, no. 3, pp. 658-667, 2009.
78. L. Redmond, A. H. Kashani, andA. Ghosh, "Calciumregulation of dendritic growth via CaM kinase IV and CREB-mediated transcription, " Neuron, vol. 34, no. 6, pp. 999-1010, 2002.
79. R. Waltes, E. Duketis, M. Knapp et al., "Common variants in genes of the postsynaptic FMRP signalling pathway are risk factors for autism spectrum disorders, " Human Genetics, vol. 133, no. 6, pp. 781-792, 2014.
80. X. Yu and R. C. Malenka, "-catenin is critical for dendritic morphogenesis, " Nature Neuroscience, vol. 6, no. 11, pp. 1169-1177, 2003.
81. R. C. Malenka and M. F. Bear, "LTP and LTD: an embarrassment of riches, " Neuron, vol. 44, no. 1, pp. 5-21, 2004.
82. M. A. Bemben, S. L. Shipman, T. Hirai et al., "CaMKII phosphorylation of neuroligin-1 regulates excitatory synapses, " Nature Neuroscience, vol. 17, no. 1, pp. 56-64, 2014.
83. L.-H. Zeng, Y. Ouyang, V. Gazit et al., "Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex, " Neurobiology of Disease, vol. 28, no. 2, pp. 184-196, 2007.
84. K. Kuroda, S. Yamada, M. Tanaka et al., "Behavioral alterations associated with targeted disruption of exons 2 and 3 of the Disc1 gene in the mouse, " Human Molecular Genetics, vol. 20, no. 23, pp. 4666-4683, 2011.
85. S. H. Yun and B. L. Trommer, "Fragile X mice: reduced long-term potentiation and N-Methyl-D-Aspartate receptormediated neurotransmission in dentate gyrus, " Journal of Neuroscience Research, vol. 89, no. 2, pp. 176-182, 2011.
86. J. E. Chubb, N. J. Bradshaw, D. C. Soares, D. J. Porteous, and J. K. Millar, "The DISC locus in psychiatric illness, " Molecular Psychiatry, vol. 13, no. 1, pp. 36-64, 2008.
87. H. Kilpinen, T. Ylisaukko-Oja, W. Hennah et al., "Association of DISC1 with autism and Asperger syndrome, " Molecular Psychiatry, vol. 13, no. 2, pp. 187-196, 2008.
88. A. Crepel, J. Breckpot, J.-P. Fryns et al., "DISC1 duplication in two brothers with autism and mild mental retardation, " Clinical Genetics, vol. 77, no. 4, pp. 389-394, 2010.
89. K. K. Singh, G. De Rienzo, L. Drane et al., "Common DISC1 polymorphisms disruptWnt/GSK3 signaling and brain development, " Neuron, vol. 72, no. 4, pp. 545-558, 2011.
90. J. Boucher, A. Mayes, and S. Bigham, "Memory in autistic spectrum disorder, " Psychological Bulletin, vol. 138, no. 3, pp. 458-496, 2012.
91. D. M. Bowler, S. B. Gaigg, and J. M. Gardiner, "Binding of multiple features in memory by high-functioning adults with autism spectrum disorder, " Journal of Autism and Developmental Disorders, vol. 44, no. 9, pp. 2355-2362, 2014.
92. E.-M. Hur and F.-Q. Zhou, "GSK3 signalling in neural development, " Nature Reviews Neuroscience, vol. 11, no. 8, pp. 539-551, 2010.
93. F. Benedetti, A. Bernasconi, C. Lorenzi et al., "A single nucleotide polymorphism in glycogen synthase kinase 3-promoter gene influences onset of illness in patients affected by bipolar disorder, " Neuroscience Letters, vol. 355, no. 1-2, pp. 37-40, 2004.
94. C. Hooper, R. Killick, and S. Lovestone, "The GSK3 hypothesis of Alzheimer's disease, " Journal of Neurochemistry, vol. 104, no. 6, pp. 1433-1439, 2008.
95. R. P. Souza, M. A. Romano-Silva, J. A. Lieberman, H. Y. Meltzer, A. H. C. Wong, and J. L. Kennedy, "Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response, " Psychopharmacology, vol. 200, no. 2, pp. 177-186, 2008.
96. Y. Mao, X. Ge, C. L. Frank et al., "Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling, " Cell, vol. 136, no. 6, pp. 1017-1031, 2009.
97. W. Guo, A. C. Murthy, L. Zhang et al., "Inhibition of GSK3 improves hippocampus-dependent learning and rescues neurogenesis in a mouse model of fragile X syndrome, " Human Molecular Genetics, vol. 21, no. 3, Article ID ddr501, pp. 681-691, 2012.
98. Y. Luo, G. Shan, W. Guo et al., "Fragile X mental retardation protein regulates proliferation and differentiation of adult neural stem/progenitor cells, " PLoS Genetics, vol. 6, no. 4, Article ID e1000898, 2010.
99. M. A. Mines, C. J. Yuskaitis, M. K. King, E. Beurel, and R. S. Jope, "GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism, " PLoS ONE, vol. 5, no. 3, Article ID e9706, 2010.
100. T. A. Comery, J. B. Harris, P. J. Willems et al., "Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits, " Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 10, pp. 5401-5404, 1997.
101. J. Pec, C. Feliciano, J. T. Ting et al., "Shank3 mutant mice display autistic-like behaviours and striatal dysfunction, " Nature, vol. 472, no. 7344, pp. 437-442, 2011.
102. S. V. Dindot, B. A. Antalffy, M. B. Bhattacharjee, and A. L. Beaudet, "The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology, " Human Molecular Genetics, vol. 17, no. 1, pp. 111-118, 2008.
103. C. Latapy, V. Rioux, M. J. Guitton, and J.-M. Beaulieu, "Selective deletion of forebrain glycogen synthase kinase 3 reveals a central role in serotonin-sensitive anxiety and social behaviour, " Philosophical Transactions of the Royal Society B: Biological Sciences, vol. 367, no. 1601, pp. 2460-2474, 2012.
104. F. Hernndez, J. Borrell, C. Guaza, J. Avila, and J. J. Lucas, "Spatial learning deficit in transgenic mice that conditionally overexpress GSK-3 in the brain but do not form tau filaments, " Journal of Neurochemistry, vol. 83, no. 6, pp. 1529-1533, 2002.
105. S. M. Ochs, M. M. Dorostkar, G. Aramuni et al., "Loss of neuronal GSK3 reduces dendritic spine stability and attenuates excitatory synaptic transmission via-catenin, " Molecular Psychiatry, 2014.
106. P. Chen, Z. Gu, W. Liu, and Z. Yan, "Glycogen synthase kinase 3 regulates N-methyl-D-aspartate receptor channel trafficking and function in cortical neurons, "Molecular Pharmacology, vol. 72, no. 1, pp. 40-51, 2007.
107. L.-Q. Zhu, S.-H. Wang, D. Liu et al., "Activation of glycogen synthase kinase-3 inhibits long-termpotentiationwith synapseassociated impairments, "TheJournal ofNeuroscience, vol. 27, no. 45, pp. 12211-12220, 2007.
108. T. Ma, N. Tzavaras, P. Tsokas, E. M. Landau, and R. D. Blitzer, "Synaptic stimulation of mTOR is mediated by Wnt signaling and regulation of glycogen synthetase kinase-3, " The Journal of Neuroscience, vol. 31, no. 48, pp. 17537-17546, 2011.
109. A. Verrotti, A. Scaparrotta, M. Cofini, F. Chiarelli, and G. M. Tiboni, "Developmental neurotoxicity and anticonvulsant drugs: a possible link, " Reproductive Toxicology, vol. 48, pp. 72-80, 2014.
110. G. Chen, L.-D. Huang, Y.-M. Jiang, and H. K. Manji, "The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3, " Journal of Neurochemistry, vol. 72, no. 3, pp. 1327-1330, 2000.
111. C. J. Phiel, F. Zhang, E. Y. Huang, M. G. Guenther, M. A. Lazar, and P. S. Klein, "Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen, " The Journal of Biological Chemistry, vol. 276, no. 39, pp. 36734-36741, 2001.
112. A. L. Christianson, N. Chesler, andJ. G. R. Kromberg, "Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs, " Developmental Medicine & Child Neurology, vol. 36, no. 4, pp. 361-369, 1994.
113. K. Miyazaki, N. Narita, and M. Narita, "Maternal administration of thalidomide or valproic acid causes abnormal serotonergic neurons in the offspring: implication for pathogenesis of autism, " International Journal of Developmental Neuroscience, vol. 23, no. 2-3, pp. 287-297, 2005.
114. T. Schneider and R. Przewocki, "Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism, " Neuropsychopharmacology, vol. 30, no. 1, pp. 80-89, 2005.
115. G. C. Wagner, K. R. Reuhl, M. Cheh, P. McRae, and A. K. Halladay, "Anewneurobehavioralmodel of autism in mice: preand postnatal exposure to sodium valproate, " Journal of Autism and Developmental Disorders, vol. 36, no. 6, pp. 779-793, 2006.
116. S. J. Harrison-Uy and S. J. Pleasure, "Wnt signaling and forebrain development, " Cold Spring Harbor Perspectives in Biology, vol. 4, no. 7, Article ID a008094, 2012.
117. T. Rinaldi, K. Kulangara, K. Antoniello, and H. Markram, "Elevated NMDA receptor levels and enhanced postsynaptic longterm potentiation induced by prenatal exposure to valproic acid, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 33, pp. 13501-13506, 2007.
118. E. Kumamaru, Y. Egashira, R. Takenaka, and S. Takamori, "Valproic acid selectively suppresses the formation of inhibitory synapses in cultured cortical neurons, "Neuroscience Letters, vol. 569, pp. 142-147, 2014.
119. Z. Wang, L. Xu, X. Zhu et al., "Demethylationof specificWnt/-catenin pathway genes and its upregulation in rat brain induced by prenatal valproate exposure, " The Anatomical Record, vol. 293, no. 11, pp. 1947-1953, 2010.
120. Y. Zhang, Y. Sun, F. Wang, Z. Wang, Y. Peng, and R. Li, "Downregulating the canonical Wnt/-catenin signaling pathway attenuates the susceptibility to autism-like phenotypes by decreasing oxidative stress, " Neurochemical Research, vol. 37, no. 7, pp. 1409-1419, 2012.
121. Y. Zhang, C. Yang, G. Yuan, Z. Wang, W. Cui, and R. Li, "Sulindac attenuates valproic acid-induced oxidative stress levels in primary cultured cortical neurons and ameliorates repetitive/stereotypic-like movement disorders in Wistar rats prenatally exposed to valproic acid, " International Journal of Molecular Medicine, vol. 35, no. 1, pp. 263-270, 2015.
122. A. Gupta, T. G. Schulze, V. Nagarajan et al., "Interaction networks of lithium and valproate molecular targets reveal a striking enrichment of apoptosis functional clusters and neurotrophin signaling, " The Pharmacogenomics Journal, vol. 12, no. 4, pp. 328-341, 2012.
123. P. S. Klein and D. A. Melton, "A molecular mechanism for the effect of lithium on development, " Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 16, pp. 8455-8459, 1996.
124. K. Takuma, Y. Hara, S. Kataoka et al., "Chronic treatment with valproic acid or sodium butyrate attenuates novel object recognition deficits and hippocampal dendritic spine loss in a mouse model of autism, " Pharmacology Biochemistry and Behavior, vol. 126, pp. 43-49, 2014.
125. M. Siegel, C. A. Beresford, M. Bunker et al., "Preliminary investigation of lithiumfor mood disorder symptoms in children and adolescents with autism spectrum disorder, " Journal of Child and Adolescent Psychopharmacology, vol. 24, no. 7, pp. 399-402, 2014.
126. X. Wu, Y. Bai, T. Tan et al., "Lithium ameliorates autistic-like behaviors induced by neonatal isolation in rats, " Frontiers in Behavioral Neuroscience, vol. 8, article 234, 2014.
127. Z.-H. Liu, T. Huang, and C. B. Smith, "Lithium reverses increased rates of cerebral protein synthesis in a mouse model of fragile X syndrome, " Neurobiology of Disease, vol. 45, no. 3, pp. 1145-1152, 2012.
128. Z.-H. Liu, D.-M. Chuang, and C. B. Smith, "Lithiumameliorates phenotypic deficits in a mouse model of fragile X syndrome, " International Journal of Neuropsychopharmacology, vol. 14, no. 5, pp. 618-630, 2011.
129. R. R. Seese, A. R. Maske, G. Lynch, andC. M. Gall, "Long-term memory deficits are associated with elevated synaptic ERK1/2 activation and reversed by mGluR5 antagonism in an animal model of autism, " Neuropsychopharmacology, vol. 39, no. 7, pp. 1664-1673, 2014.
130. C. J. Yuskaitis, M. A. Mines, M. K. King, J. D. Sweatt, C. A. Miller, and R. S. Jope, "Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mousemodel of fragile X syndrome, " Biochemical Pharmacology, vol. 79, no. 4, pp. 632-646, 2010.
131. R. M. Gandhi, C. S. Kogan, and C. Messier, "2-Methyl-6-(phenylethynyl) pyridine (MPEP) reverses maze learning and PSD-95 deficits in Fmr1 knock-out mice, " Frontiers in Cellular Neuroscience, vol. 8, article 70, 2014.
132. J. T. Gass and M. F. Olive, "Transcriptional profiling of the rat frontal cortex following administration of the mGlu5 receptor antagonistsMPEP and MTEP, " European Journal of Pharmacology, vol. 584, no. 2-3, pp. 253-262, 2008.